About us
About MyoTherix, Inc.
MyoTherix, Inc. is a venture-supported biotechnology company focused on developing novel therapeutics for the treatment of muscle disorders. Its lead product opportunity utilizes an innovative and novel approach to target both cardiac and skeletal muscle weakness. We are a clinical-stage drug discovery and development company advancing innovative therapies for patients suffering from Charcot Marie Tooth disease, Duchenne muscular dystrophy, and other rare neuromuscular disorders for which there are no adequate treatment.
MyoTherix’s lead research program intends to improve both cardiac and skeletal muscle function, as well as reduce inflammation and facilitate new muscle regeneration. We are pleased to work with the team at CureDuchenne and look forward to developing this new approach to the treatment of this devastating disease.